Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30050566 | 1.00 | PIM1 (0.33) | PIM1PIM3PIM2PARP1DDB1 | |
| SCHEMBL30780279 | 0.92 | PARP1 (0.31) | PIM1PIM3PIM2PARP1 | |
| SCHEMBL26983732 | 0.85 | KDM4E (0.31) | PARP1KDM4ELMNANPC1RAB9A | |
| SCHEMBL30119787 | 0.84 | PARP1 (0.35) | PARP1KDM4ELMNANPC1RAB9A | |
| SCHEMBL26983725 | 0.83 | JMJD6 (0.30) | — | |
| SCHEMBL26983763 | 0.81 | TLR8 (0.35) | PARP1KDM4ELMNANPC1RAB9A | |
| SCHEMBL30051006 | 0.81 | TLR8 (0.35) | PARP1KDM4ELMNANPC1RAB9A | |
| SCHEMBL29156455 | 0.78 | JMJD6 (0.33) | — | |
| SCHEMBL26991434 | 0.78 | TYK2 (0.43) | TYK2 | |
| SCHEMBL30780297 | 0.77 | PARP1 (0.33) | PARP1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001898-A1 | Heteroaryl compounds as inhibitors of TYK2/JAK1, composition and application thereof | ACCRO BIOSCIENCE HK LTD (HK) | 2026-01-01 | — | — | US | disclosed |
| WO-2024010963-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2/JAK1, COMPOSITION AND APPLICATION THEREOF | ACCRO BIOSCIENCE (HK) LIMITED (CN) | 2024-01-11 | — | — | WO | disclosed |
| WO-2024010963-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2/JAK1, COMPOSITION AND APPLICATION THEREOF | ACCRO BIOSCIENCE (HK) LIMITED (CN) | 2024-01-11 | — | — | WO | disclosed |
| CN-115466289-A | Compound with TYK2 inhibitory activity, pharmaceutical composition containing same, and application thereof | 爱科诺生物医药(香港)有限公司 | 2022-12-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001898-A1 | Heteroaryl compounds as inhibitors of TYK2/JAK1, composition and application thereof | JAK1, JAK2, TYK2 | PIM1 432/4885PIM3 389/4885PIM2 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.